

2024 AGM Chairman Address and Investor Presentation

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, herein provides the Chairman Address and Investor Presentation to the 2024 Annual General Meeting (AGM) of shareholders to be held today at the offices of BDO Australia - Melbourne, Collins Square, Tower 4, Level 18, 727 Collins St, Docklands VIC 3008 at 9:00am (AEDT).

Chairman Address to Shareholders

The agenda for the Meeting today will be as follows: I will start by providing a brief overview of Neurotech, our key highlights from the 2024 financial year (FY2024), including our clinical and financial developments and corporate governance. I will then outline the Meeting procedures and continue to the formal items of business.

Following the completion of the formal items, Executive Director Dr Tom Duthy will then give a presentation of Neurotech's core development platform, clinical trials, strategic initiatives and our outlook for the 2025 financial year.

FY2024 was one of substantial progress for Neurotech. Neurotech focussed its resources on the accelerated clinical development of our proprietary broad-spectrum cannabinoid drug therapy NTI164 across three difficult to treat paediatric neurological disorders, namely Autism Spectrum Disorder (ASD), Rett Syndrome and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. We are focused on developing NTI164 for neurological disorders where there is strong evidence of persistent or progressive neuroinflammation. All three opportunities represent a combined addressable market opportunity of approximately US\$7.2 billion per annum, with limited or no safe and effective therapies currently available.

During FY2024, our open-label Phase I/II clinical trials in Rett Syndrome and PANDAS/PANS met their respective primary endpoints and a number of key secondary endpoints, while our double-blind, placebo-controlled Phase II/III clinical trial in ASD also reported the primary endpoint had been met, along with all secondary endpoints available to date. Importantly, across all three clinical trials, NTI164 once again showed an excellent safety and tolerability profile, with just one serious adverse event recorded across all 94 patients to date (including into our long-term extensions). Adverse events were mild and included some nausea and vomiting in a small number of patients, which is most likely attributable to the oil-based carrier. These results represent a significant achievement for a small development company like Neurotech. All patients who have elected to do so, have received NTI164 for 52 weeks or longer under the extension phase of the trials. Our longest ASD patient has now received therapy for nearly 200 weeks, and our last Rett Syndrome patient will cross over 52 weeks of daily therapy in the first quarter of the next calendar year.

The execution of these trials has been exemplary. We would like to thank our three clinical investigators, Professor Michael Fahey, Professor Russell Dale and Associate Professor Carolyn Ellaway for their commitment to their patients in seeking safe and effective therapies like NTI164 for their patients, where safe and effective therapies are desperately needed.

For personal use only

In April, Neurotech announced the appointment of Mr Robert Maxwell Johnston as a Non-Executive Director. Prior to his non-executive director career, Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the world's largest healthcare company for 11 years. In addition, the Company announced the resignation of Mr Winton Willesee as a Non-Executive Director. On behalf of the Board of Neurotech and its shareholders, we wish to thank Mr Willesee for his valuable contributions to the Company during his time in office since his appointment to the board in April 2019.

FY2024 saw the further development of Neurotech's manufacturing capabilities that it has established to produce NTI164. This allows the company to support the patients who continue on the extension phase of NTI's four clinical trials as well as the registration enabling toxicology programs. Neurotech through its strategic partner Fenix Innovation Group ("Fenix") has established three separate manufacturing sites in Australia to produce NTI164. All sites are unrelated to the Company's existing license/licensor for neurological disorders and are managed by Fenix. The Company intends to continue to develop this manufacturing capability as it moves towards a possible registration of NTI164 in the future.

During the year, we successfully raised capital via a share placement following our excellent Phase II/III ASD results, and top-line Phase I/II Rett Syndrome clinical data. Neurotech received \$10 million with support from existing and new institutional, professional and sophisticated Australian and overseas investors.

We are in the final stages of finalising our 2024 R&D tax incentive filing and anticipate receiving a rebate of at least \$2.5 million on eligible R&D spend during FY24. When coupled with our 30 September 2024 cash balance of \$8.7 million, our pro-forma cash position of \$11.2 million, will allow the company to complete all current IND-enabling studies including animal toxicology work and a human pharmacokinetic trial in preparation for planned regulatory meetings with the US FDA and Australian TGA during the 2025 calendar year.

Recently, we announced the appointment of Dr Anthony Filippis as Managing Director and CEO of Neurotech International. Anthony will bring to Neurotech a significant amount of experience across the life sciences sector, with an outstanding track record of partnering success and capital markets expertise. On behalf of the Board, we welcome Anthony to the role and look forward to his contribution in executing our NTI164 strategy once he commences on 1 February 2025.

In September and November, Neurotech announced the results of the proteomic and genomic analysis on PANDAS/PANS patients, that participated in the Company's Phase I/II clinical trial, which confirmed that NTI164 normalises immune system gene expression and protein production. This significant finding has led to two further patent applications by the Company. Neurotech has now developed a strong Intellectual Property position and directly owns a portfolio of patent applications associated with the composition of different cannabinoids, their use in neurological disorders and modification of proteomic and genomic pathways in humans.

Finally, on behalf of the Board of Directors, we once again would like to thank our paediatric patients, their caregivers, our clinicians and our committed shareholders for their support of Neurotech over the last year. As a Board we certainly believe our current share price does not reflect the significant progress we have made, and the sound financial position of the Company as we embark on an exciting year ahead.

We look forward to updating our various stakeholders throughout the year ahead, which holds great promise for Neurotech International.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD during Q4 CY2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

For personal use only

For personal use only

Improving Lives



Investor Presentation 2024 Annual General Meeting

Dr Tom Duthy
Executive Director

20 November 2024

Disclaimer



For personal use only

IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.


Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Neurotech Four Core Strategies



**Focus on Paediatric
Patients**



**Focus On Rare
Neurological Disorders
with Neuroinflammation**



**Focus on Partnering
with Key Opinion
Leaders / Clinicians**




**Focus On Drug Product
Development**

For personal use only

Therapeutic Agent: NTI164

For personal use only



NTI164 – Ideal Target Product Profile

For personal use only



Prescription Only Medicine



FDA, EMA, TGA Approved



Multiple Paediatric Neurological Disorders



Premium Pricing Reflecting Clinical Investment




Reimbursed



Orphan Designations + Other Regulatory Levers

Clinical Pipeline – 2024

For personal use only



1. Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
2. Autism Spectrum Disorder

Autism | Rett | PANDAS/PANS

*“The goals of treatment for **Autism** are to improve core deficits in social communication and social interactions and minimize the impact of restricted behaviours, with an overarching goal to help children develop greater functional skills and independence.”¹*

*“Caregivers of children with **Rett** experience the illness as being like an “obstacle course”, where they must continuously overcome hurdles. These include hindrances for finding responses to their symptoms and achieving a diagnosis, for managing the treatment and daily care, and for finding the essential financial resources to meet all the expenses generated by the illness.”²*

*“We encourage clinicians, teachers, providers, extended family, and friends to understand the human aspects of **PANDAS/PANS** as symptoms are often so distressing, causing high levels of caregiver burden.”³*




For personal use only

1. Weitlauf AS, McPheeters ML, Peters B, et al. Therapies for Children With Autism Spectrum Disorder: Behavioural Interventions Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Aug. (Comparative Effectiveness Review, No. 137.) Introduction.
2. Palacios-Ceña D, Famoso-Pérez P, Salom-Moreno J, Carrasco-Garrido P, Pérez-Corrales J, Paras-Bravo P, Güeita-Rodríguez J. “Living an Obstacle Course”: A Qualitative Study Examining the Experiences of Caregivers of Children with Rett Syndrome. International Journal of Environmental Research and Public Health. 2019; 16(1):41
3. <https://aspire.care/what-is-pans/caregiver-experience/>

Intellectual Property – 2024


Strong Patent Position

Neurotech has three patent families to underpin future worldwide commercialisation in neurological applications of NTI164. Two families have now entered the national phase and one family has entered the international (PCT) phase.



Other IP & Barriers to Entry

Vertically Integrated: Seed to Patient Controlled
(Trade Secret: continuity of production to SOP, extraction(s))



Orphan Drug Designation(s)

10 Years
7 Years


Market Exclusivity from Approval – Europe
Market Exclusivity from Approval – United States




For personal use only

Clinical Trials, Treatment Durations

All patients can continue on NTI164 'extension' – additional long-term safety and efficacy collected



● Primary and Secondary Endpoint Analysis




94

Children treated with NTI164 in a clinical trial and extension studies

2+

Years of daily oral treatment with NTI164 and counting




For personal use only

NT1164 Efficacy is Strong, Durable and Consistent

Autism (Phase II/III)

For personal use only

56% Improvement in Severity of illness at 12 weeks




46% Patients much Improved / improved at 8 weeks

Significant Improvements in Adaptive Behaviours

Rett

100% of patients improved by week 20




57% of patients "very much / much improved"

60% Improvement in patient/caregiver quality of life

PANDAS/PANS

38% Improvement in Severity of illness at 52 weeks




45% Improvement in anxiety / depression at 52 weeks

2024 Corporate Strategy

For personal use only




Global Partnering



- Secure one or more strategic partnerships for NTI164 in the United States, Europe and certain Asian territories to support clinical, regulatory development, manufacturing and future market launches
- In 2023, at least 49 deals were announced involving rare neurological diseases, with disclosed values totalling US\$13.2 billion



AU Registration(s)




- Seek provisional registration pathway for NTI164 initially for either PANDAS/PANS or Rett Syndrome (i.e. the orphan disease franchise)
- Provisional registration(s) can save up to two years of development and a provisionally registered prescription medicine may be able to receive reimbursement. Follow with ASD (large market in AU)



For personal use only



Australian Market



Rett Syndrome: 380 pts | threshold to pay N/A | Market N/A




PANDAS/PANS: 1000 pts | threshold to pay \$100k | Market \$100m



ASD: 169k pts | threshold to pay \$35.3k | Market \$5.9Bn¹



Global (US,EU) Market



Rett Syndrome: 9,500 pts | threshold to pay US\$0.36m² | Market US\$2Bn



PANDAS/PANS: 14,000 pts | threshold to pay US\$100k | Market US\$1.2Bn



ASD: 4.2m pts | threshold to pay N/A | Market US\$3+Bn¹

1. The AU market based on threshold to pay calc. on NDIS recipients for NTI164, whereas US/EU based on Market Reports (Grandview Research, Virtue Market Research) on current drugs used 2. US market only DAYBUE™ (trofinetide) can be up to US\$1,000 per day N/A – Not available. Source: Neurotech market estimates, Neurotech Presentations, ASX Release 12 August 2024 based on various data sources, Neuren Pharma presentation dated 28 August 2023.

Key Milestones – NTI164

1H CY2024

- HREC/TGA Approval Cerebral Palsy Phase I/II Clinical Trial
- 24-week PANDAS/PANS Phase I/II Clinical Trial Data
- Rett Syndrome Phase I/II 52-week Extension HREC Approval
- Results of ASD Phase II/III Clinical Trial
- Top-line Rett Syndrome Phase I/II Clinical Trial data
- Results of Rett Syndrome Phase I/II Clinical Trial – full data
- Meeting outcome – TGA¹ Regulatory Advice

2H CY2024

- Appointment of A/Prof Carolyn Ellaway as CMO
- Filing of Orphan Drug Designation USA – PANDAS/PANS + Rett Syndrome
- Additional Phase II/III 12 Week Cross-Over Results – ASD
- Metabologenomic data from Phase I/II PANDAS/PANS Clinical Trial
- HREC approval human pharmacokinetic (PK) Phase I clinical trial
- Orphan Drug Designation USA – Rett Syndrome
- Continuation of FDA IND / EMA² enabling toxicology program
- Commencement of the Phase I human PK trial
- Orphan Drug Designation Europe – Rett Syndrome (Q1 CY2025)

For personal use only

For personal use only



Neurotech

International

Contact Details

Dr Tom Duthy
Executive Director
td@neurotechinternational.com
+61 402 493 727

*This presentation has been authorised by the Board of Neurotech International Limited

www.neurotechinternational.com

Neurotech International Limited (ASX: NTI)